Skip to main content
Comparing Outcomes and Toxicities With Standard and Reduced Dose Melphalan in Autologous Stem Cell Transplant Patients With Multiple Myeloma
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Comparing Outcomes and Toxicities With Standard and Reduced Dose Melphalan in Autologous Stem Cell Transplant Patients With Multiple Myeloma
User login
Username
Password
Reset your password
Concept
Lead
score
Multiple Myeloma
1
1
Transplantation
0
0.77
Toxicology
0
0.65
Stem Cell Research and Therapy
0
0.56
Mucositis
0
0.39
Intensive Care Unit
0
0.33
Board Certification
0
0.19
Clinical Research
0
0.19
Neutrophils
0
0.19
Plasma
0
0.19
Tennessee
0
0.19
Diarrhea
0
0.08
Healthcare and Medical Technology
0
0.08
Neutropenia
0
0.08
Specialty
Lead
score
Hematology-Oncology
1
1
Emergency Medicine
0
0.74
Public Health & Prevention
0
0.65
Transplantation
0
0.65
Family Medicine/Primary Care
0
0.62
Internal Medicine
0
0.31
Critical Care
0
0.14
Hospital Medicine
0
0.14
Edit Tags